Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high-and intermediate-risk myelofibrosis (MF). Several other JAK inhibitors are in development with some currently undergoing phase-3 clinical trial testing. None of the currently available JAK inhibitors are specific to mutant JAK2; their mechanism of action involves attenuation of JAK-STAT signaling with downregulation of proinflammatory cytokines, rather than selective suppression of the disease clone. Accordingly, while ruxolitinib and other JAK inhibitors are effective in controlling splenomegaly and alleviating constitutional symptoms, their benefit in terms of reversing bone marrow fibrosis or inducing complete or partial remissions appears to be limited. The experience to date with ruxolitinib shows that despite its salutary effects on quality of life, over half of the patients discontinue treatment within 2-3 years. In the current perspective, we examine the incidence and causes of ruxolitinib 'treatment failure' in MF patients based on our personal experience as well as a review of the published literature. We also discuss the challenges in defining and classifying ruxolitinib failure, and within the context of several clinical scenarios, we provide recommendations for the post-ruxolitinib management of MF patients.
The natural history of primary MF (PMF) has now been relatively well defined; analysis of mature data sets such as that recently reported from the Mayo Clinic (64% deaths, median follow-up for living patients = 7.7 years) revealed a median survival of 5.9 years from the time of referral to that center and an approximately 7% leukemic transformation rate. 4 PMF patients can be risk stratified in terms of survival on the basis of either clinical risk models such as the Dynamic International Prognostic System-plus, 6 or increasingly, on the basis of the underlying myeloproliferative neoplasms-relevant mutational profile. 4, [7] [8] [9] In terms of the latter, the presence of type 1/type 1-like CALR exon 9 mutations is associated with the most favorable survival outcome while the absence of JAK2/MPL/CALR mutations (that is, 'triple negative') is associated with the most unfavorable outcome. 4 Furthermore, the presence of increasing number of prognostically detrimental/'high molecular risk' mutations (that is, ASXL1, EZH2, SRSF2 and/or IDH-1/2 genes) conferred a progressively worse survival outcome, independent of traditional risk factors. 7 
TREATMENT OF MF BEFORE THE ADVENT OF JAK INHIBITORS
Drug therapy for PMF is not curative and has not been shown to display disease-modifying activity. 10 Therefore, allogeneic stem cell transplant (ASCT) is often considered if the goal of therapy is to prolong survival. 11 ASCT for PMF is potentially curative but its value has been undermined by treatment-related complications, including death. In general, asymptomatic patients with low/ intermediate-1 risk MF can be observed without specific treatment or with palliative therapy; androgens, prednisone, danazol, thalidomide and lenalidomide are used for the treatment of anemia and hydroxyurea for splenomegaly. In addition, splenectomy might be considered for drug-refractory splenomegaly and involved field radiotherapy for post-splenectomy hepatomegaly and non-hepatosplenic extramedullary hematopoiesis.
DEVELOPMENT OF JAK INHIBITORS FOR MF
Synopsis of the ruxolitinib story JAK inhibitors for treatment of MF, including PMF and postpolycythemia vera or post-essential thrombocythemia MF, were first introduced in the form of INCB018424 (Ruxolitinib), a JAK-1/2 inhibitor, in a phase 1/2 study (NCT00509899). On the basis of promising preliminary results in terms of treatment-induced reduction in splenomegaly and improvement in MF-related symptoms (dose limiting toxicity was reversible thrombocytopenia; maximum tolerated dose was 25 mg twice daily or 100 mg once daily), 12 ruxolitinib was rapidly evaluated in two phase 3 registration trials, namely COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544).
COMFORT I was a randomized double-blind placebo-controlled trial in patients with intermediate-2 or high-risk MF with palpable splenomegaly; the ruxolitinib starting dose was 20 mg or 15 mg twice daily based on the pre-study baseline platelet count. 13 Unblinding of the study-drug assignments and crossover from placebo to ruxolitinib was permitted for protocol-defined worsening splenomegaly (⩾25% increase in spleen volume from baseline). Of the 155 patients randomized to ruxolitinib, 41.9% achieved the primary end point (that is, ⩾ 35% reduction in spleen volume by magnetic resonance imaging or computed tomography at week 24 as compared with baseline) versus 0.7% in the placebo arm (P o 0.001). Similarly, a greater proportion of patients on the ruxolitinib arm (45.9%) versus placebo (5.3%) met the key secondary end point of ⩾ 50% decrease in the 6 item total symptom score (derived from a modified MF Symptom Assessment Form) (P o 0.001).
In COMFORT-II, patients were randomly assigned, in a 2:1 ratio, to receive ruxolitinib or best available therapy (BAT), the latter including any commercially available agents or no therapy (47% received hydroxyurea,16% glucocorticoids and 33% no therapy). 14 Patients receiving BAT who met protocol-specified criteria (underwent splenectomy or had an increase in spleen volume of 425% from the nadir during the study period) could crossover to receive ruxolitinib therapy. Of the 146 patients randomized to ruxolitinib, 28% achieved the primary end point (that is, ⩾ 35% reduction in spleen volume at week 48 as compared with baseline) versus 0% in the BAT arm (P o0.001). Similarly, a greater proportion of patients on the ruxolitinib arm (32%) versus placebo (0%) met the key secondary end point of ⩾ 35% reduction in spleen volume at week 24 as compared with baseline. On the basis of the aforementioned data, ruxolitinib was licensed for treatment of intermediate-and high-risk MF in the United States in 2011. 15 
WHAT IS THE INCIDENCE OF RUXOLITINIB TREATMENT FAILURE?
In the absence of a clearcut definition, the rate of ruxolitinib treatment discontinuation may provide an indirect estimate of treatment failure, although this proxy does not distinguish between 'true treatment failure' versus discontinuation for other reasons (for example, loss of insurance coverage and onset of a severe comorbid illness). In COMFORT-I and COMFORT-II, ruxolitinib discontinuation rates were approximately 50% by 3 years. 16, 17 However, another study based on US claims database inquiry suggested much higher rates (up to 50% within 6 months) of discontinuation in routine clinical practice. 18 Our experience is similar to the latter report; in a phase 1/2 study (NCT00509899), ruxolitinib discontinuation rates among 51 patients treated at our site at 1, 2 and 3 years were 51, 72 and 89%, respectively. 19 Conversely, ruxolitinib discontinuation rates for 107 patients treated at the other study site at 1, 2 and 3 years were 24, 36 and 46%, respectively. 20 
POTENTIAL CAUSES OF RUXOLITINIB TREATMENT FAILURE IN MF
Lessons from phase 3 clinical trials Resistance Primary resistance (refractoriness): Most MF patients achieve at least some degree of spleen size reduction with ruxolitinib therapy; however, the minimum degree of splenic response that confers therapeutic benefit remains undefined. 13, 14 In contrast, while most patients randomized to ruxolitinib in COMFORT-I had at least some improvement in symptoms at week 24 as compared with baseline, a small but not insignificant proportion (not quantified in the manuscript) had worse symptoms at this time point. 13 Secondary resistance (Splenic relapse): COMFORT-I and COMFORT-II defined 'loss of spleen response' as spleen volume that was no longer ⩽ 35% reduced as compared with baseline and increased by ⩾ 25% from the nadir. The cumulative spleen response (⩾35% reduction in spleen volume) at last follow-up was 59 and 51% for patients randomized to ruxolitinib in COMFORT-I and COMFORT-II, respectively. 16, 17 By 3 years, the median duration of spleen response by the aforementioned criteria had not been reached.
Treatment-related toxicities. The rate of study discontinuation due to adverse events (AEs) was similar between the two study arms in both COMFORT-I and COMFORT-II. 13, 14 Non-hematological toxicities (mostly grades 1/2 in severity) were also comparable; however, ecchymosis, dizziness, diarrhea and headache occurred more frequently in patients randomized to ruxolitinib. Cytopenias were observed more frequently in patients treated with ruxolitinib as compared with placebo or BAT. In COMFORT-I, rates of grades 3/4 anemia were 45 versus 19%, thrombocytopenia 13 versus 1% and neutropenia 7 versus 2%. 13 The mean hemoglobin level nadir (9.5 g/dl, from 10.9 g/dl at baseline) and highest red blood cell transfusion rate (40%, from 25% at baseline) were seen at 8-12 weeks after starting ruxolitinib treatment, with partial recovery by week 24. 13, 14 In contrast, the mean platelet count decreased by approximately 50% (320 to 170 × 10 9 /l) in patients randomized to ruxolitinib, without recovery over time. 17 Of note, both studies mandated modifications in the ruxolitinib dose in response to thrombocytopenia or neutropenia; in general, patients randomized to 20 mg and 15 mg twice daily were titrated down to 15 mg and 10 mg twice daily, respectively. 16, 17 In COMFORT-II, 63% of ruxolitinib versus 15% of BAT patients required dose reduction or interruption for AEs, particularly for thrombocytopenia in the ruxolitinib arm (41 versus 1%).
14 Disease progression, including leukemic transformation. In COM-FORT-I, two patients and zero patient in the ruxolitinib and placebo arms, respectively, developed acute myeloid leukemia (AML) per the initial report.
13 By 3 years, four patients in each arm had developed AML. 17 In COMFORT-II, after a median follow-up of 151 weeks, five (3%) and three (4%) patients developed AML in the ruxolitinib and BAT arms, respectively. 16 A recent report indicated a relatively high incidence of extramedullary AML in ruxolitinib-treated patients. 21 Among 40 patients treated over 2 years, 5 patients (13%) developed AML, of which 4 patients developed isolated extramedullary leukemia.
Withdrawal symptoms on temporary or permanent drug discontinuation. Among patients who interrupt or discontinue ruxolitinib treatment, MF symptoms relapse to baseline levels in approximately 1 week. 13 In COMFORT-I, AEs of ⩾ grade 3 were reported in 16 and 57% of patients after ruxolitinib interruption and discontinuation, respectively (versus 13 and 46% in placebo arm). 13 While no clear pattern of AEs after discontinuing ruxolitinib was recognized in either COMFORT-I or COMFORT-II, others have reported serious AEs manifesting as respiratory distress, shock, capillary leak, tumor lysis syndrome, splenic infarction and/or disseminated intravascular coagulation with fibrinolysis (DIC/ICF) in this setting. [22] [23] [24] On occasion, withdrawal events may occur even in the context of preemptive measures such as tapering of ruxolitinib dose and administration of concurrent corticosteroid and/or myelosuppressive (for example, hydroxyurea) therapies. Severe AEs have been reported in some, 25 but not other studies, 26, 27 in the context of pre-planned ruxolitinib discontinuation before ASCT; in one study, 7 of 10 patients developed serious AEs (7 were life-threatening, 2 fatal) within 21 days of discontinuation. 25 Events of cardiogenic shock, tumor lysis syndrome/acute renal failure and steroid-refractory acute graftversus-host disease were reported.
Early mortality. COMFORT-I showed a survival benefit for patients randomized to ruxolitinib versus placebo after a median follow-up Ruxolitinib treatment failure in myelofibrosis A Pardanani and A Tefferi of 51 weeks (13 (8%) versus 24 deaths (16%); hazard ratio = 0.5, 95% confidence interval (CI) = 0.25-0.98). 13 After a median followup of 149 weeks however, this survival advantage was lost (42 (27%) versus 54 deaths (35%); hazard ratio = 0.69, 95% CI = 0.46-1.03). 17 In contrast, COMFORT-II showed no survival advantage for ruxolitinib versus BAT after a median follow-up of 61 weeks (11 (8%) versus 4 deaths (5%); hazard ratio = 1.01, 95% CI = 0.32-3.24).
14 After a median follow-up of 151 weeks however, a survival advantage for ruxolitinib versus BAT was reported (29 (20%) versus 22 deaths (30%); hazard ratio = 0.48, 95% CI = 0.28-0.85). 16 These analyses are confounded by the study design that permitted treatment crossover. For instance, in COMFORT-I, a high proportion of patients in the placebo arm either discontinued treatment (27%) or crossed over to receive ruxolitinib early in the study (73%; median time to crossover = 41 weeks). Further, higher treatment discontinuation rates have been reported for patients randomized to ruxolitinib versus the comparator arms for both COMFORT-I and COMFORT-II studies. 28, 29 This may introduce a selection bias that cannot be compensated either by subject randomization or by intent-to-treat survival analyses.
DEFINING RUXOLITINIB TREATMENT FAILURE IN MF
Defining ruxolitinib failures in the context of routine clinical practice Currently, there is no consensus on what specific criteria define failure versus suboptimal response to ruxolitinib treatment in MF. In this regard, routine clinical practice remains at significant variance from conduct of clinical trials; specifically, imaging studies and symptom assessment questionnaires for assessment of spleen and symptom response, respectively, are not routinely utilized. The FDA label for ruxolitinib provides limited guidance in terms of dose reductions for thrombocytopenia, potential drugdrug interactions and impaired liver and/or kidney function, and also for dose increases mainly for inadequate spleen response. 15 Defining ruxolitinib failures in the context of clinical trials Development of other JAK inhibitor drugs is currently ongoing, including several in clinical trials that target patients who have received prior ruxolitinib therapy. This constitutes an attractive niche for drug development given the current lack of FDAlicensed drugs for the ruxolitinib 'relapsed/refractory' setting. Given the absence of a standard definition for ruxolitinib failure, several ad hoc solutions have been implemented in postruxolitinib clinical trials.
Simply require prior ruxolitinib exposure (without mandating that any pre-defined criteria for ruxolitinib failure be met). In the JAKARTA-2 study (NCT01523171), eligibility criteria for 'ruxolitinib failure' required prior exposure to ruxolitinib for at least 14 days. 30 While this approach is practical and relatively unbiased, it relies entirely on physician/investigator judgment in terms of assigning whether a patient has failed ruxolitinib treatment. The basis of ruxolitinib failure in this context can be expected to be nonuniform and the underlying patient heterogeneity could complicate efforts to understand which aspects of ruxolitinib failure are amenable to being favorably modified by second-line therapies.
Specify study-specific criteria for ruxolitinib failure. In the ongoing phase 3 study of momelotinib versus BAT in MF (NCT02101268), eligibility criteria include prior exposure to ruxolitinib for at least 28 days with either a requirement for red blood cell transfusions while on ruxolitinib treatment or a need to adjust dose of ruxolitinib to o 20 mg twice daily for either ⩾ grade 3 thrombocytopenia or anemia or hematoma. While this approach provides a more specific definition of ruxolitinib failure, a potential disadvantage is that it is study specific and excludes certain patient subgroups who could also reasonably be considered as having failed ruxolitinib treatment (see examples below). Further, such definitions can be biased toward a patient population considered more likely to respond to the second-line therapy being tested, so as to increase the probability of a positive study outcome. 37 Hypomethylating agents (that is, 5-azacitidine or decitabine) have limited value. [38] [39] [40] [41] [42] Formal studies in the latter regard are ongoing (NCT02076191). Management options a. Spleen response generally regained with ruxolitinib dose increase (if feasible). b. If minimum efficacious dose of ruxolitinib cannot be maintained, then consider alternative therapy, including other JAK inhibitors. Although anecdotal reports of efficacy exist, the value and toxicity of adding hydroxyurea or interferon-α remains to be formally studied.
CLINICAL SCENARIOS ILLUSTRATING FAILURE OF FIRST-LINE RUXOLITINIB TREATMENT AND OUR PROPOSED MANAGEMENT OPTIONS FOR EACH SCENARIO
5. Loss of spleen response: on a stable ruxolitinib treatment dose a. If associated with worsening cytopenias, increasing leukocytosis and circulating blasts, evidence for clonal evolution, then disease progression is likely. b. If not associated with above features, consider treatment noncompliance (rare), drug-drug interaction or gastrointestinal malabsorption that decreases exposure to ruxolitinib.
Management options
a. If data suggest disease progression and/or clonal evolution, then manage as Section #3 above. b. Check for drug-drug interaction (for example, concurrent treatment with a strong CYP3A4 inducer), malabsorption, and patient compliance with ruxolitinib. c. If clinically efficacious dose of ruxolitinib cannot be reached (in the absence of disease progression), then consider alternative therapy including other JAK inhibitors.
Serious opportunistic infection: treatment-related immunosuppression
a. Ruxolitinib is immunosuppressive, potentially through inhibition of dendritic cell function. 43, 44 b. Severe opportunistic infections have been described, including C. neoformans and P. jiroveci pneumonia, 45, 46 
CONCLUSIONS AND FUTURE DIRECTIONS
It is becoming increasingly evident that ruxolitinib is discontinued in over half of MF patients within the first 2-3 years of starting such therapy. Consequently, there is a critical need to clarify the causes of drug discontinuation and develop a working definition of 'treatment failure', especially in the context of clinical trials to permit comparison of treatment results across studies. In this regard, we underscore the need to distinguish between (i) primary treatment resistance, (ii) sub-optimal response, (iii) disease relapse, (iv) disease progression, (v) AEs and (vi) other reasons. Notably, drug discontinuation may ensue from more than one of the aforementioned reasons and may also be confounded by 'mixed response'; the latter implies the concomitant presence of both treatment response and reasons for drug interruption/ discontinuation. A related goal also of critical importance is to clarify the clinical outcome (including survival) as well as the response to subsequent therapies in MF patients following ruxolitinib 'treatment failure'. The correlation between specific causes of treatment failure and clinical outcome as well as response to second-line therapies may point to significant differences in the disease biology between MF patients. These observations will likely inform our therapeutic approach, in particular with regard to the aggressiveness of subsequent treatment that is selected. For example, if development of isolated late cytopenias not reversible by ruxolitinib dose reduction/treatment interruption is found to be associated with a higher risk of disease progression and/or poor survival, then it may bias toward consideration of early ASCT versus other salvage medical therapies.
The ruxolitinib discontinuation data may also drive the choice of initial therapy in certain situations. For example, in a patient with intermediate-1 risk MF with significant splenomegaly-related symptoms, ruxolitinib may be an appropriate initial choice for treatment to palliate symptoms. If however this patient is found to harbor a poor-risk molecular/mutation profile (for example, ASXL1 +/CALR-), 8 the predicted median life expectancy decreases from 6 years to 3 years. Furthermore, there is a minimum 50% probability of discontinuing ruxolitinib treatment for some reason within 2-3 years, and the efficacy of post-ruxolitinib 'failure' salvage therapies is not well established. In this context, ruxolitinib is unlikely to provide for long-term disease control and consideration of ASCT early as opposed to at time of disease relapse/progression may be warranted.
In our opinion, the '2013 IWG response criteria' and '2014 ELN-IWG clinical end points for drug treatment trials' documents provide a good starting point for discussion on how to define 'true treatment failure' with ruxolitinib. 55, 56 For instance, primary resistance is indicated by the absence of onset of any clinical response within 28 days of starting treatment. Suboptimal response is indicated by either the failure to achieve a minimum clinical improvement response within 12 weeks or a 'mixed response' wherein supervening AEs (for example, cytopenias) complicate a clinical improvement or better clinical response, particularly if ruxolitinib dose reduction or treatment interruption is necessary. Disease relapse is indicated by loss of a previously confirmed (clinical improvement or better) clinical response or disease progression by leukemic transformation. Drug discontinuation due of other reasons would be considered separately. Ideally, post-ruxolitinib clinical trial subjects should be stratified based on the aforementioned classification so we understand which second-line therapies provide the best fit for specific clinical scenarios.
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